Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of September 2014. The registrant is a foreign private issuer based in Petach-Tikva, Israel, focused on biopharmaceutical development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event-based disclosure rather than a financial statement.
Material Changes
The primary material event reported is the issuance of a U.S. patent by the US Patent and Trademark Office on September 30, 2014. The patent covers the company's CF102 drug candidate for the treatment of liver regeneration and function following liver surgery.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the general context of the patent issuance. The document incorporates a press release (Exhibit 99.1) by reference but does not detail its contents within the body of the filing.
Investor Verification Checklist
- Verify the scope and claims of the U.S. patent issued for the CF102 drug candidate.
- Review the full text of the September 30, 2014 press release (Exhibit 99.1) for additional details on the patent's commercial implications.
- Confirm the current development stage and regulatory status of CF102 for liver regeneration.